LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-mediated Apoptosis via miR-513a-3p in Human Gastric Cancer

References

• Peleteiro B, Padr P, Castro C, Ferro A, Morais S, Lunet N. Worldwide burden of gastric cancer in 2012 that could have been prevented by increasing fruit and vegetable intake and predictions for 2025. Br J Nutri. 2016;115(5):851–859. doi:10.1017/S000711451500522X
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Kamiya S, Rouvelas I, Lindblad M, Nilsson M. Current trends in gastric cancer treatment in Europe. J Cancer Metastasis Treat. 2018;4:35–46. doi:10.20517/2394-4722.2017.76
   Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.26808342
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi:10.1016/j.canlet.2017.04.02428476483
   PubMed Web of Science ®Google Scholar
• An Y, Zhang Z, Shang Y, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6(5):e1766. doi:10.1038/cddis.2015.12325996293
   PubMed Web of Science ®Google Scholar
• Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12(2):204–213. doi:10.3748/wjg.v12.i2.20416482619
   PubMed Web of Science ®Google Scholar
• Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer (Review). Oncol Lett. 2016;11(5):2959–2964. doi:10.3892/ol.2016.433727123046
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159. doi:10.1038/nrg252119188922
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li H, Fang S, et al. NONCODE 2016: an informative and valuable data source of long non-coding RNAs. Nucleic Acids Res. 2016;44(D1):D203–D208. doi:10.1093/nar/gkv125226586799
   PubMed Web of Science ®Google Scholar
• Yan D, Cao H, Feng J. Advances of long non-coding RNA UCA1 in cancers. J Int Oncol. 2017;44(2):108–111.
   Google Scholar
• Wang X, Peng F, Cheng L, et al. Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas. Oncotarget. 2017;8(17):28373. doi:10.18632/oncotarget.1605928423704
   PubMedGoogle Scholar
• Liu H, Wang G, Yang L, Qu J, Yang Z, Zhou X. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/β-catenin pathway. PLoS One. 2016;11(12):e0168406. doi:10.1371/journal.pone.016840627977766
   PubMed Web of Science ®Google Scholar
• Han Y, Yang Y-N, Yuan H-H, et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology. 2014;46(5):396–401. doi:10.1097/PAT.000000000000012524977734
   PubMed Web of Science ®Google Scholar
• Li Z, Wang X, Dang Y, et al. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis. Eur Rev Med Pharmacol Sci. 2020;24:591–603.32016960
   PubMed Web of Science ®Google Scholar
• Horita K, Kurosaki H, Nakatake M, Ito M, Kono H, Nakamura T. Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun. 2019;516(3):831–838. doi:10.1016/j.bbrc.2019.06.12531262449
   PubMed Web of Science ®Google Scholar
• Pan J, Li X, Wu W, et al. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 2016;382(1):64–76. doi:10.1016/j.canlet.2016.08.01527591936
   PubMed Web of Science ®Google Scholar
• Liu C, Jiang F, Zhang X, Xu X. Long Non-Coding RNA UCA1 modulates paclitaxel resistance in breast cancer via miR-613/CDK12 axis. Cancer Manag Res. 2020;12:2777. doi:10.2147/CMAR.S24196932425595
   PubMed Web of Science ®Google Scholar
• Wang J, Ye C, Liu J, Hu Y. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun. 2018;501(4):1034–1040. doi:10.1016/j.bbrc.2018.05.10429777711
   PubMed Web of Science ®Google Scholar
• Luo Z, Kang G. Long non-coding RNA UCA1 enhances drug resistance of lung cancer cells via activating mTOR signaling. Int J Clin Exp Pathol. 2016;9(2):1408–1415.
   Web of Science ®Google Scholar
• Wang H, Guan Z, He K, Qian J, Cao J, Teng L. LncRNA UCA1 in anti-cancer drug resistance. Oncotarget. 2017;8(38):64638. doi:10.18632/oncotarget.1834428969100
   PubMedGoogle Scholar
• Gu W, Ren JH, Zheng X, Hu XY, Hu MJ. Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA network involved in gastric cancer progression. Mol Med Rep. 2019;20(3):2209–2218.31322220
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Nagano O, et al. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). Gastric Cancer. 2017;20(6):1004–1009. doi:10.1007/s10120-017-0720-y28466360
   PubMed Web of Science ®Google Scholar
• Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, Phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–510. doi:10.1016/S2468-1253(19)30083-431101534
   PubMed Web of Science ®Google Scholar
• Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53. doi:10.1186/s13046-017-0528-y28407783
   PubMed Web of Science ®Google Scholar
• Zhai J, Shen J, Xie G, et al. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Lett. 2019;454:37–43. doi:10.1016/j.canlet.2019.04.00230978440
   PubMed Web of Science ®Google Scholar
• Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet. 2018;19(9):535–548. doi:10.1038/s41576-018-0017-y29795125
   PubMed Web of Science ®Google Scholar
• Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.26666209
   PubMed Web of Science ®Google Scholar
• Hanly D, Esteller M, Berdasco M. Altered Long Non-coding RNA Expression in Cancer: potential Biomarkers and Therapeutic Targets? 2019.
   Google Scholar
• Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non‐codingRNAin cancer. Cancer Sci. 2018;109(7):2093–2100. doi:10.1111/cas.1364229774630
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu J, Xing R, et al. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012;77(3):488–494. doi:10.1016/j.lungcan.2012.05.10722749944
   PubMed Web of Science ®Google Scholar
• Li S, Xu Y-N, Niu X, Li Z, Wang J-F. miR-513a-5p targets Bcl-2 to promote dichlorvos induced apoptosis in HK-2 cells. Biomed Pharmacother. 2018;108:876–882. doi:10.1016/j.biopha.2018.09.10130372899
   PubMed Web of Science ®Google Scholar
• Morvan VL, Laroche-Clary A, Robert J. Genetic polymorphisms of cytochrome P450 1B1 (CYP1B1) are linked to the response to chemotherapy: studies of in vitro models. Bull Cancer. 2010;97:S47–S47.
   PubMed Web of Science ®Google Scholar
• Morvan VL, Auzanneau C, Pasquies A, Brault M, Robert J, Lansiaux A. Abstract 2200: relationship between cytochrome P450 1B1 (CYP1B1) and head and neck cancer cells proliferation, dissemination and chemosensitivity to anticancer drugs. Cancer Res. 2013;73(8 Supplement):2200.
   Google Scholar
• Nishida CR, Everett S, Ortiz dM, PR. Specificity determinants of CYP1B1 estradiol hydroxylation. Mol Pharmacol. 2013;84(3):451–458. doi:10.1124/mol.113.08770023821647
   PubMed Web of Science ®Google Scholar
• Jacob A, Potin S, Chapy H, et al. Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure. Brain Res. 2015;1613:27–36. doi:10.1016/j.brainres.2015.03.04925858487
   PubMed Web of Science ®Google Scholar
• Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett. 2012;324(1):13–30. doi:10.1016/j.canlet.2012.04.02122561558
   PubMed Web of Science ®Google Scholar
• Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol. 2001;41(1):297–316. doi:10.1146/annurev.pharmtox.41.1.29711264459
   PubMed Web of Science ®Google Scholar
• Zhu Z, Mu Y, Qi C, Wang J, Zhao F. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med. 2014;35(2):340–348. doi:10.3892/ijmm.2014.204125516145
   PubMed Web of Science ®Google Scholar
• Mu W, Hu C, Zhang H, et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015;25(4):477–495. doi:10.1038/cr.2015.2325698578
   PubMed Web of Science ®Google Scholar
• Kwon YJ, Baek HS, Ye DJ, Shin S, Chun YJ. CYP1B1 inhibits cancer cell apoptosis through sp1-mediated suppression of trail expression. Drug Metab Pharmacokinet. 2017;32(1):S39. doi:10.1016/j.dmpk.2016.10.166
   Web of Science ®Google Scholar